Compare Applied Digital Corporation (APLD) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Digital Corporation vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Applied Digital Corporation trades at $30.65 (market cap $8.90B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $294.72 (market cap $7.94B). The key difference: Applied Digital Corporation and Bio-Rad Laboratories, Inc. Class A Common Stock are close in size by market cap. Which is the better fit depends on your goals.
| APLD | BIO | |
|---|---|---|
Market Cap | $8.90B | $7.94B |
Sector | Technology | Health |
52-Week High | $49.65 | $339.75 |
52-Week Low | $9.18 | $241.71 |
Enterprise Value | $10.00B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
BIO trades at $296.11, down 0.39% today, with a bullish technical outlook supported by moving averages and a consensus price target of $305. The company reported $2.58B revenue in 2025 with net income of $759.90M, showing a significant turnaround from prior losses. Recent news highlights Nasdaq compliance restoration and participation in industry events, reinforcing operational stability.
BIO presents a positive investment case with strong analyst support (53.85% buy ratings) and improving profitability, though high P/E of 49.27 and recent earnings misses pose valuation and execution risks. Upside potential exists if the company meets future earnings expectations, but investors should monitor debt levels and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
